Epigenetics of Schizophrenia

Srivastava, A. K.; Dada, Oluwagbenga; Qian, Jessica; Al-Chalabi, Nzaar; Fatemi, Ali; Gerretsen, Philip; Graff, Ariel; Luca, Vincenzo De

doi:10.1016/j.psychres.2021.114218

Cited by 40 publications

(27 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additional research is needed to identify microRNA expression signatures that link metabolic liver disease with psychiatric disorders. Finally, microRNAs are being explored as potential diagnostic biomarkers and therapeutics for NAFLD/NASH ( Di Mauro et al, 2021 ; Mohamed et al, 2021 ) and myriad psychiatric disorders as well ( Alural et al, 2017 ; Roy et al, 2020 ; Islam et al, 2021 ; Srivastava et al, 2021 ; Tsermpini et al, 2022 ).…”

Section: Mechanistic Synergies Between Non-alcoholic Fatty Liver Dise...mentioning

confidence: 99%

Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines

et al. 2022

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world and one of the leading indications for liver transplantation. It is one of the many manifestations of insulin resistance and metabolic syndrome as well as an independent risk factor for cardiovascular disease. There is growing evidence linking the incidence of NAFLD with psychiatric illnesses such as schizophrenia, bipolar disorder and depression mechanistically via genetic, metabolic, inflammatory and environmental factors including smoking and psychiatric medications. Indeed, patients prescribed antipsychotic medications, regardless of diagnosis, have higher incidence of NAFLD than population norms. The mechanistic pharmacology of antipsychotic-associated NAFLD is beginning to emerge. In this review, we aim to discuss the pathophysiology of NAFLD including its risk factors, insulin resistance and systemic inflammation as well as its intersection with psychiatric illnesses.

show abstract

Section: Mechanistic Synergies Between Non-alcoholic Fatty Liver Dise...mentioning

confidence: 99%

Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The therapeutic potential of non-coding RNA is that they can affect cognition by targeting a large number of genes and signaling pathways simultaneously, such as multiple pathways within a single neuron ( Kocerha et al, 2015 ). In SCZ, researchers measured the expression of multiple miRNAs in patient serum and postmortem brain ( Srivastava et al, 2021 ). SCZ patients with miR-137 risk alleles show more severe negative symptoms and cognitive impairment.…”

Section: Epigeneticsmentioning

confidence: 99%

Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention

Wang

Meng

Liu

et al. 2022

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Psychiatric diseases, such as schizophrenia, bipolar disorder, autism spectrum disorder, and major depressive disorder, place a huge health burden on society. Cognitive impairment is one of the core characteristics of psychiatric disorders and a vital determinant of social function and disease recurrence in patients. This review thus aims to explore the underlying molecular mechanisms of cognitive impairment in major psychiatric disorders and identify valuable biomarkers for diagnosis, treatment and prevention of patients.

show abstract

“…A group of scientists studied the expression of nuclear and mitochondrial RNA in the frontal cortex in cases of schizophrenia and found significantly increased expression of the mitochondrial gene of the 2 nd subunit of cytochrome oxidase. Four other genes were related to mitochondrial ribosomal RNA (Srivastava et al, 2021).…”

Section: Schizophreniamentioning

confidence: 99%

Analysis of significance of mitochondrial dysfunction in the pathogenesis of diseases of the central nervous system

Sokolik

Prozorova²

2022

Neurosci Res Notes

View full text Add to dashboard Cite

One of the promising therapy areas for many diseases of the central nervous system is the search for agents of selective effect on mitochondria. Both the mitochondria themselves and the mitochondrial metabolism of the transformed cell of the central nervous system and activation of energy metabolism by reprogrammed mitochondria give impetus for the development of mitochondrial pharmacology to use the special properties of transformed cells mitochondria as targets for neuroprotective and neuroplastic effects. In this review, we analyse literary sources of domestic and foreign authors about the influence of mitochondrial dysfunction on various links in the pathogenesis of central nervous system diseases. Based on currently available data, scientists divided all signs of mitochondrial dysfunction in schizophrenia into three groups: morphological disorders of mitochondria, signs of a violation of the oxidative phosphorylation system and dysregulation of genes responsible for mitochondrial proteins. The therapeutic effect of drugs for central nervous system disorders should focus on reducing the accumulation of metabolic products and tissue breakdown, restoring mitochondrial functions and synaptic plasticity, and protecting mitochondria from toxic effects, thereby alleviating cognitive disorders with a neuroprotective effect.

show abstract

Epigenetics of Schizophrenia

Cited by 40 publications

References 101 publications

Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines

Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines

Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention

Analysis of significance of mitochondrial dysfunction in the pathogenesis of diseases of the central nervous system

Contact Info

Product

Resources

About